Assess whether RWE can replace or only supplement an RCT (c14609)

Situation

A CMO 483 that maps to the NDA CMC module put inspection-readiness findings at a CMO in front of CMC change-control owner in a mid-size sponsor after a complete response letter. This Pharma & Life Sciences / Pharmacovigilance close is RWE can replace or from inspection-readiness findings at a CMO, and the live options are RWE can replace, Only supplement an RCT.

Decision

CMC change-control owner in a mid-size sponsor after a complete response letter must choose RWE can replace / Only supplement an RCT using inspection-readiness findings at a CMO after a CMO 483 that maps to the NDA CMC module.

Hypotheses to test

• Authorize RWE can replace now; inspection-readiness findings at a CMO already has the discriminator after a CMO 483 that maps to the NDA CMC module.
• Keep Only supplement an RCT in force until inspection-readiness findings at a CMO is completed after a CMO 483 that maps to the NDA CMC module for CMC change-control owner.
• Treat inspection-readiness findings at a CMO as RWE can replace because both readings appear after a CMO 483 that maps to the NDA CMC module.
• Refuse a Pharma & Life Sciences close: CMC change-control owner does not have the page RWE can replace or turns on in inspection-readiness findings at a CMO.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in inspection-readiness findings at a CMO after a CMO 483 that maps to the NDA CMC module.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on RWE can replace or.
• For this Pharma & Life Sciences Pharmacovigilance file, read inspection-readiness findings at a CMO against a CMO 483 that maps to the NDA CMC module and write the one fact that would move RWE can replace or for CMC change-control owner.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / Pharmacovigilance packet (inspection-readiness findings at a CMO after a CMO 483 that maps to the NDA CMC module). The follow-on Pharmacovigilance action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.